Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(40%)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_1
2
40%
Ph phase_2
2
40%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Recruiting2
Not yet recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)

Trials by Status

recruiting240%
not_yet_recruiting240%
terminated120%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_1

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951
recruitingphase_2

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

NCT07366801
recruitingnot_applicable

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

NCT07184853
not_yet_recruitingphase_1

REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

NCT06607367
terminatedphase_2

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

NCT02962388

Clinical Trials (5)

Showing 5 of 5 trials
NCT07464951Phase 1

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Not Yet Recruiting
NCT07366801Phase 2

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Recruiting
NCT07184853Not Applicable

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

Recruiting
NCT06607367Phase 1

REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

Not Yet Recruiting
NCT02962388Phase 2

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5